Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors

American Journal of Alzheimer's Disease and Other Dementias
Xiaodong ShiCan Gao

Abstract

Cholinesterase inhibitors (ChEIs), represented by donepezil, rivastigmine, and galantamine, used to be the only approved class of drugs for the treatment of Alzheimer's disease. After the approval of memantine by the Food and Drug Administration (FDA), N-methyl-d-aspartic acid (NMDA) receptor antagonists have been recognized by authorities and broadly used in the treatment of Alzheimer's disease. Along with complementary mechanisms of action, NMDA antagonists and ChEIs differ not only in therapeutic effects but also in adverse reactions, which is an important consideration in clinical drug use. And the number of patients using NMDA antagonists and ChEIs concomitantly has increased, making the matter more complicated. Here we used the FDA Adverse Event Reporting System for statistical analysis , in order to compare the adverse events of memantine and ChEIs. In general, the clinical evidence confirmed the safety advantages of memantine over ChEIs, reiterating the precautions of clinical drug use and the future direction of antidementia drug development.

References

Feb 19, 2002·The Annals of Pharmacotherapy·Mohamed A Omar, James P Wilson
Apr 16, 2002·Pharmacopsychiatry·M HeinzeR Grohmann
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Pierre N TariotUNKNOWN Memantine Study Group
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
Nov 30, 2005·International Journal of Geriatric Psychiatry·Suzanne V FrankfortJos H Beijnen
Feb 11, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·O L LopezS T Dekosky
Feb 25, 2009·Expert Opinion on Drug Safety·Harish Kavirajan
Feb 28, 2009·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Corinne G Husten
Apr 1, 2007·Neuropsychiatric Disease and Treatment·Rajesh R Tampi, Christopher H van Dyck
Apr 10, 2009·Pharmacoepidemiology and Drug Safety·A Bate, S J W Evans
Apr 10, 2009·Pharmacoepidemiology and Drug Safety·Elisabetta PoluzziFabrizio De Ponti
Jun 3, 2009·Alzheimer Disease and Associated Disorders·George GrossbergJean-Marc Orgogozo
Jul 1, 2007·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ron BrookmeyerH Michael Arrighi
Oct 2, 2009·Journal of the American Geriatrics Society·Rohini K HernandezElizabeth V Lawler
Mar 4, 2011·Interdisciplinary Sciences, Computational Life Sciences·Lun YangLin He
Mar 25, 2011·Pharmacoepidemiology and Drug Safety·Carlotta FranchiAlessandro Nobili
Apr 8, 2011·Science Translational Medicine·David M HoltzmanAlison M Goate
Jun 1, 2012·British Journal of Pharmacology·Wojciech Danysz, Chris G Parsons
Feb 26, 2013·Archives of Pharmacal Research·Preet Anand, Baldev Singh
Mar 20, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Jun 25, 2013·Pharmacoepidemiology and Drug Safety·Marie-Laure LarocheUNKNOWN French Centres of Pharmacovigilance Network
Aug 15, 2014·American Journal of Alzheimer's Disease and Other Dementias·Christine J Jensen, Jennifer Inker
Sep 13, 2014·BMC Neurology·Carina WattmoLennart Minthon
Apr 23, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Jue Jiang, Hong Jiang

❮ Previous
Next ❯

Citations

Aug 23, 2016·BioMed Research International·J Mendiola-PrecomaG Garcia-Alcocer
Mar 10, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Xinmeng SongLong Zeng
Jul 10, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dileep K Vijayan, Kam Y J Zhang
Dec 30, 2020·International Journal of Biological Macromolecules·K V DileepKam Y J Zhang
Apr 22, 2021·CNS & Neurological Disorders Drug Targets·Himanshi Varshney, Yasir Hasan Siddique

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

OpenFDA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.